header("Access-Control-Allow-Origin: *"); ?>
therapeuticpublished patents
oncologypublished patents
research tools
diagnosticpublished patents
Welcome to our Technology Offers website You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.
Diagnostic
Research
Therapeutic
Flow Cytometry
Immunocytochemistry
Immunoprecipitation
In vivo studies
Western Blot
Cardiovascular Diseases
Central Nervous System
Dermatology
Ear nose throat disease
Gastrointestinal Diseases
Genetic Disorders
Genito Urinary System
Hematological Disorders
Immunology
Musculoskeletal
Nutritional disorder
Oncology
Ophtalmology
Respiratory Disease
Women health
Others
Infectious diseases
GABA is an inducer of α-to-β-like cell conversion in vivo. This conversion induces α cell replacement mechanisms through the mobilization of […]
The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. […]
Despite the notion that human CD8+ T cells are the final mediators of autoimmune β- cell destruction in type 1 diabetes (T1D), none of their target […]
Despite the notion that human CD8+ T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target […]
Type 1 diabetes (TID) is an autoimmune disease that results from the selective destruction of insulin-producing β-cells in pancreatic islets. The […]
The present invention relates to methods and pharmaceutical compositions of inducing immune […]
Despite the notion that human CD8+ T cells are the final mediators of autoimmune β-cell destruction […]
Despite the notion that human CD8+ T cells are the final mediators of autoimmune β- cell […]
GABA is an inducer of α-to-β-like cell conversion in vivo. This conversion induces α cell […]
Type 1 diabetes (TID) is an autoimmune disease that results from the selective destruction of […]
Research tool licensing team
researchtools@inserm-transfert.fr
User accounts are momentarily unavailable
The Inserm Transfert website is currently undergoing maintenance. It will be available again in a few hours.